INTRODUCTION
An important feature of the HIV is its vast genetic diversity and rapid evolution that influence the pathogenesis, transmission, diagnosis, and clinical management of the infection [1] . Such a high genetic variation is due to the lack of a proofreading mechanism by reverse transcriptase, resulting in a mutation rate of 10 -5 changes per replicative cycle. The virus also has a large population size and high capacity to recombine, adding to its genetic complexity [2, 3] . After transmission, HIV evolves rapidly from the transmitted/founder virus within an infected individual. The immune response contributes to the intrahost diversification, selecting for both cell-mediated and antibody-mediated escape mutants [4, 5] . Moreover, different cellular milieu or changes in the population of susceptible cells can drive diversification within a particular compartment, as well as change cell tropism and coreceptor usage [6] . Other host factors, such as apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC), play a role in HIV diversity by introducing G to A mutations. The interplay of all these factors explains why viral sequences within an individual can differ by 10% or more [7] . The major implications of viral diversity are the rapid selection for drug-resistant mutations by suboptimal antiretroviral treatment (ART) and the difficulties it imposes on the development of vaccines and curative strategies. In this review article, we will address how viral diversity and evolution are affected by ART and why early treatment may be a prerequisite to achieving a functional cure for HIV.
INTRAPATIENT HIV DIVERSITY
HIV populations in acute infection have been described as being mostly homogeneous, resulting from the productive transmission of a single viral variant or, less frequently, heterogeneous, resulting from the transmission of multiple variants [8, 9] . After transmission, viral diversity typically accumulates in early infection, strongly influenced by pressures imposed by our immune systems, and then plateaus in chronic infection [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] 18 & ]. Kearney et al. [9] showed that transmitted HIV variants carried cytotoxic T lymphocyte (CTL) escape mutations that were selected along the chain of transmission. These mutations persisted for years in the recipients, even at CTL epitopes that were not recognized by the new host's major histocompatibility complexes. The persistence of these CTL mutations was concurrent with the selection of new escape mutations in epitopes that were recognized by the recipient's own major histocompatibility complexes, contributing the accumulation of HIV diversity within patients and in the population as a whole [9] . Maldarelli et al. [18 & ] subsequently showed that CTL escape mutations continued to be selected during chronic infection, despite plateaus in the overall diversity of the virus populations. Rare HIV-infected individuals, termed elite controllers, do not have the typical pattern of HIV replication and diversification. Plasma HIV RNA levels in these patients are below the limit of detection by standard clinical assay seven without therapy. Mens et al. [19] analyzed the viral genetics of longitudinally sampled plasma from elite controllers and showed that HIV continued to evolve throughout the course of infection but that the immune systems of the elite controllers are likely more successful in limiting the number of cells that become infected. Such controllers are of special interest because they may reveal specific mechanisms of immune control without ART and, thus, be of great importance for the development of future vaccine and curative strategies.
The pool of HIV-susceptible cells in vivo is diverse and includes T cells, macrophages, dendritic cells, and other cell types. Long-lived, resting CD4 þ T cells constitute what has been defined as the latent reservoir for HIV and area of significant target of eradication strategies. A molecular characterization of noninduced proviruses in resting CD4 þ T cells revealed that most proviruses were rendered defective due to mutations introduced during reverse transcription or by APOBEC3G (A3G) [20 && ,21,22] . A3G is a host enzyme with cytidine deaminase activity that results in the alteration of the nucleotide sequence from cytidine-to-uridine at the RNA level in the single-stranded negative strand and, therefore, become fixed in the viral DNA as guanosine-to-adenosine mutations in the plus strand. However, the complementary DNA integration can take place despite these mutations, resulting in the accumulation of hypermutated proviruses within the pool-infected cells. A recent analysis of the gag region from noninduced proviruses showed that about one out of three sequences contained A3G-mediated G-to-A changes [20 && ].
HIV COMPARTMENTALIZATION
Understanding the distribution and persistence of infected cells across tissues is critical to characterizing the sources of viremia before, during, and after therapy. The term compartmentalization was introduced to indicate tissues or cell types wherein viral replication is ongoing, but viral gene flow (in and out) is restricted because of anatomical barriers [23] . Extensive compartmentalization in the central nervous system was reported and found to be strongly associated with the development of HIVassociated dementia [24] . However, studies of compartmentalization of HIV populations in gutassociated lymphoid tissues (GALT) have yielded contrasting results. Van Marle et al. [25] analyzed sequences from the esophagus, stomach, duodenum, and colorectum and reported compartmentalized viral replication in the gut, suggesting a role of the gut milieu in shaping HIV diversity, but Imamichi et al. [26 & ] characterized sequences from blood, ileum, and colon and found variants to be indistinguishable from those in the plasma. Such contrasting results may be explained by sampling bias, inadequate phylogenetic signal of the genomic regions analyzed, or varying levels of expansion of infected cells across tissues. Multiple reports have suggested HIV compartmentalization between the genital tract and the blood [27, 28] . However, two studies from Bull et al. [29, 30] revealed that the tissue-specific sequences detected had very low genetic diversity, suggesting that expanded infected cells could lead to local bursts of expression, which may cause a bias for statistical analyses of
KEY POINTS
Rapid HIV evolution results in diverse viral populations without treatment.
Optimal ART prevents further HIV evolution, suggesting that replication is effectively halted during treatment.
Some long-lived, infected cells can proliferate and express virions, making them a source of persistent viremia during ART.
Persistent cells harboring replication-competent proviruses are the main obstacles for HIV eradication.
Initiating treatment during early infection restricts HIV diversity and limits the size of the reservoir, reducing the pool of variants that must be targeted for eradication.
compartmentalization. Studies [31, 32] 
DYNAMICS OF VIRAL DECAY ON ANTIRETROVIRAL THERAPY
The dynamics of plasma HIV RNA decay after initiating ART can be divided into four phases [35] [36] [37] . The phases of decay are shown in Fig. 1 show that HIV infected cells decline initially on ART but then achieve a steady state by maintaining a balance between infected long-lived cells, expanding cells, and dying cells.
EFFECT OF ANTIRETROVIRAL THERAPY ON HIV DIVERSITY
Recent studies have assessed the effect of ART on HIV genetic diversity and evolution when treatment is initiated in early or chronic infection. Their findings are summarized in Fig. 1 [48] also showed that rebound viremia after long-term cART consisted of homogeneous populations, suggesting they may originate from the expression of the identical sequences that are present during suppression. Determining the sources for viral persistence during cART and during rebound is essential for designing strategies to eradicate HIV infection.
PROLIFERATION OF INFECTED CELLS REVEALED BY ANTIRETROVIRAL THERAPY
Homeostatic proliferation and long-term survival of infected cells have been proposed to have a leading role in HIV persistence during ART [49] . Identification of clonal sequences from clearly defective or A3G-hypermutated proviruses strongly suggested that the only way such variants could dominate and persist would be through expansion of a progenitor cell seeded by a single infection event • Larger populations of identical sequences are revealed on long-term ART.
• APOBEC3G-induced hypermutants containing stop codons are found in PBMCs during ART. Levels of plasma HIV RNA decline in four phases; the last phase has a slope close to zero [35] [36] [37] . HIV DNA declines initially on ART, but then achieves a steady state at higher levels than HIV RNA [38 & ]. When ART is initiated early after infection, diversity is halted and only one or a few variants remain after a long-term treatment [34 && ,39]. When ART is initiated early after infection, diversity is halted and only one or a few variants remain after long-term treatment [ ]. Early ART may also prevent the loss of HIV-specific immune responses to the existing variants [53, 54] . Together, the reduced size and diversity of the HIV reservoir that occurs when ART is initiated early after infection may favor immune-mediated control, as is suggested by posttherapy control of virus replication in patients from the Visconti cohort [55 & ]. The recent finding that specific HIV integration sites can lead to clonal cell expansion [50 && ] as a mechanism of infected cell persistence suggests that there may be a time-limited opportunity, through early initiation of ART, to prevent HIV integrations in key locations in the human genome that influence cell growth and survival.
CONCLUSION
Killing or permanently inactivating infected cells that persist during ART and carry proviruses that are capable of producing replication competent virions is necessary to achieve long-term remission off ART. Unfortunately, it is now clear that the reservoir for HIV is established extremely early after transmission [42 & ] and that even an extensive reduction of the reservoir to below the limit of detection of our current assays is not sufficient to achieve a longterm remission 
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